Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care

Supportive Care in Cancer

Volumn 11, Issue 2, 2003, Pages 107-113

  Barcia, Emilia ^a,c   Reyes, Rodrigo ^a   Azuara, María Luz ^b   Sánchez, Yolanda ^b   Negro, Sofía ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Asociacion Espanola Contra el Cancer   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Haloperidol; Hyoscine N butyl bromide; Palliative care; Physicochemical compatibility; Subcutaneous infusion

Indexed keywords

BUSCAPINA; HALOPERIDOL; POLYPROPYLENE; SCOPOLAMINE BUTYL BROMIDE; SODIUM CHLORIDE; ANTIEMETIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; DRUG DETERMINATION; DRUG FORMULATION; DRUG INFUSION; DRUG STABILITY; DRUG STORAGE; EXCIPIENT COMPATIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; SYRINGE; TEMPERATURE; DRUG INTERACTION; HUMAN; NEOPLASM; PALLIATIVE THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ANTIEMETICS; BUTYLSCOPOLAMMONIUM BROMIDE; DRUG INTERACTIONS; DRUG STABILITY; DRUG STORAGE; HALOPERIDOL; HUMANS; INJECTIONS, SUBCUTANEOUS; MUSCARINIC ANTAGONISTS; NEOPLASMS; PALLIATIVE CARE; TIME FACTORS;

EID: 0038412558     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-002-0415-7     Document Type: Article

References (25)

1. Zachrisson U, Fürst CJ (1998) Drug infusers in palliative medicine: a Swedish inquiry. J Pain Symptom Manage 15:299-304
2. Bruera E, Brenneis C, Michaud M, Chadwick S, Macdonald RN (1988) Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 62:407-411
3. Bruera E, Michaud M, Partignon J, Brennies C, Paterson AHG, Macdonald RN (1988) Continuous subcutaneous (sc) infusion of metoclopramide (MCO) using plastic disposable infusor for the treatment of chemotherapy induced emesis. J Pain Symptom Manage 3:105-107
4. Storey P, Herbert HH, St Louis RH, Traver EE (1990) Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 5:33-41
5. Peterson GM, Miller KA, Galloway JG, Dunne PF (1998) Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharmacol Ther 23:67-72
6. Azuara ML, Sánchez Y, Barcia E, Negro S, Reyes R (2000) Mezclas de fármacos por vía subcutánea en pacientes oncológicos. Med Paliat 7:19
7. Barcia E, Negro S, Reyes R, Sánchez Y, Azuara ML (2001) Estudio de estabilidad física y evaluación in vivo de mezclas de fármacos por vía subcutánea en pacientes oncológicos terminales. V Congress of SEFIG, Valencia, 4-6 February, p 179
8. Negro S, Azuara ML, Sánchez Y, Reyes R, Barcia E (2002) Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 10:65-70
9. Lord M, Clarke R (1995) Palliative care. Controlling gastrointestinal symptoms. Pharm J 254:511-514
10. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188-191
11. Ventafridda V, Ripamonti C, Careceni D, Spoldi E, Messina E, Conno F de (1990) The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76:389-393
12. The United States Pharmacopoeia and The National Formulary 24/19 (2000) The United States Pharmacopoeial Convention, pp 732-733
13. Plank K, Wagner K (1986) Determination of hyoscyamine and scopolamine in Datura innoxia plants by high performance liquid chromatography. Z Naturforsch 41C:391-395
14. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, Mcdowall RD, Pittman KA, Spector S (1992) Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 81:309
15. Causon R (1997) Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B 689:175-180
16. Mitrano FP, Baptista RJ, Newton DW, Augustine SC (1986) Microbial contamination potential of solutions in prefilled disposable syringes used with a syringe pump. Am J Hosp Pharm 43:78-80
17. Targett PL, Keefe PA, Merridew CG (1997) Compatibility and stability of drug adjuvants and morphine tartrate in 10 ml polypropylene syringes. Aust J Hosp Pharm 27:207-212
18. Jäppinen A, Kokki H, Naaranlahti TJ, Rasi AS (1999) Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 21:272-274
19. Lewis GBH, Hecker JF (1985) Infusion thrombophlebitis. Br J Anaesth 57:220-233
20. Fransson J, Espander-Jansson A (1996) Local tolerance of subcutaneous injections. J Pharm Pharmacol 48:1012-1015
21. Bottomly DM, Hanks GW (1990) Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 5:259-261
22. Vermeire A, Remon JP (1998) Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. Int J Pharm 174:157-177
23. Olcer M, Hakyemez, G (1988) Investigations of some physicochemical properties of haloperidol which may affect its activity. J Clin Pharmacol Ther 13:341-349
24. Huang E, Anderson RP (1994) Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 51:2963
25. Regnard C, Pashley S, Westrope F (1986) Anti-emetic diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 218-220